PAI-1

Plasminogen activator inhibitor-1

PAI-1 (Plasminogen activator inhibitor-1, also known as SERPINE1) is a member of serine protease inhibitor (SERPIN) family that acts as the primary inhibitor of two main mammalian plasminogen activators, urinary-type (uPA) and tissue-type (tPA). As the main negative regulator of plasminogen activation, PAI-1 is an essential factor in regulation of the physiological balance between thrombosis and fibrinolysis. PAI-1 is a labile molecule that exists in four different forms: active, latent, cleaved and target bound form.

High PAI-1 levels are associated with many cardiovascular diseases. PAI-1 also plays important roles in cell migration, adhesion, senescence, cancer invasion and tissue remodeling. Moreover, the PAI-1 level was extensively validated as the biological prognostic factor in breast cancer and as a marker of a poor prognosis in other cancers. PAI-1 is also one of the plasma biomarkers associated with nonalcoholic fatty liver disease. These associations have made PAI-1 an attractive pharmaceutical target.

PAI-1 Inhibitors

28-O-β-D-Glucopyranosyl pomolic acid

Cat. No.: HY-N1533

28-O-β-D-Glucopyranosyl pomolic acid is a **urokinase plasminogen activator** inhibitor with **IC_{50}** at 37.82 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

ACT001

Cat. No.: HY-128861A

ACT001 is an orally active **PAI-1** inhibitor by inhibiting the phosphorylation of **PI3K** and **AKT**. ACT001 inhibits the phosphorylation of STAT3 and PD-L1 expression by directly binding to **STAT3**.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Angstrom6

(A6 Peptide)

Cat. No.: HY-P2230

Angstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the **uPA/uPAR** cascade and abrogates downstream effects.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

AZ3976

Cat. No.: HY-117724

AZ3976 is a potent **plasminogen activator inhibitor type 1 (PAI-1)** inhibitor with an **IC_{50}** value of 26 μM in an enzymatic chromogenic assay. AZ3976 is active with an IC_{50} of 16 μM in a plasma clot lysis assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDE-096

Cat. No.: HY-120516

CDE-096 is a potent inhibitor of **PAI-1**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Diaplasinin

(PAI-749)

Cat. No.: HY-122098

Diaplasinin (PAI-749) is a plasminogen activator inhibitor-1 (**PAI-1**) inhibitor with **IC_{50}** of 295 nm. Antithrombotic efficacy.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Geodin

Cat. No.: HY-N10227

Geodin, a fungal metabolite, shows antibacterial activity. Geodin also is an inhibitor of plasminogen activator inhibitor- 1 (PAI-1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Loureirin B

Cat. No.: HY-N1504

Loureirin B, a flavonoid extracted from **Dracaena cochinchinensis**, is an inhibitor of plasminogen activator inhibitor-1 **(PAI-1)**, with an IC_{50} of 26.10μM; Loureirin B also inhibits **K_{ATP}**, the phosphorylation of **ERK** and **JNK**, and has anti-diabetic activity.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Tiplaxtinin

(PAI-039; Tiplasinin)

Cat. No.: HY-15253

Tiplaxtinin is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (**PAI-1**) with **IC_{50}** of 2.7 μM.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TM5007

Cat. No.: HY-119160

TM5007 is a poent and orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) with an **IC_{50}** of 29 μM. TM5007 enhance fibrinolysis activity and inhibits coagulation. TM5007 also prevents the fibrotic process initiated by bleomycin in mouse lung.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TM5275 sodium

Cat. No.: HY-100447

TM5275 sodium is a plasminogen activator inhibitor (**PAI-1**) with an **IC_{50}** of 6.95 μM.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TM5441

Cat. No.: HY-101761

TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (**PAI-1**), has **IC_{50}** values between 13.9 and 51.1 μM and induces intrinsic apoptosis in several human cancer cell lines.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Toddalolactone

Cat. No.: HY-N0518

Toddalolactone, a main component of Toddalia asiatica, inhibits the activity of recombinant **human plasminogen activator inhibitor-1 (PAI-1)**, with an IC_{50} value of 37.31 μM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

UK-371804

Cat. No.: HY-101214

UK-371804 is a urokinase-type plasminogen activator (**uPA**) inhibitor with a **K_i** of 10 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UKI-1

(UKI-1C)

Cat. No.: HY-100415

UKI-1 (UKI-1C) is a potent **urokinase-type plasminogen activator (uPA)** inhibitor with a **K_i** of 0.41 μM. UKI-1 is also a low molecular weight **serine protease** inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells.



Purity: 97.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Upamostat

(WX-671)

Cat. No.: HY-16511

Upamostat (WX-671) is a **serine protease** inhibitor. Upamostat is the orally available prodrug of the WX-UK1, which is a urokinase plasminogen activator (uPA) inhibitor.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ZK824190

Cat. No.: HY-126361

ZK824190 is an orally available and selective **urokinase plasminogen activator** (**uPA**) inhibitor as a potential treatment for multiple sclerosis. **IC_{50}**s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZK824190 hydrochloride

Cat. No.: HY-126361A

ZK824190 hydrochloride is an orally available and selective **urokinase plasminogen activator** (**uPA**) inhibitor as a potential treatment for multiple sclerosis. **IC_{50}**s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZK824859

Cat. No.: HY-114330

ZK824859 is an oral available and selective urokinase plasminogen activator (**uPA**) inhibitor with **IC_{50}**s of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZK824859 hydrochloride

Cat. No.: HY-114330A

ZK824859 hydrochloride is an oral available and selective urokinase plasminogen activator (**uPA**) inhibitor with **IC_{50}**s of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg